Pombiliti
Enzyme Replacement Therapy for Late-Onset Pompe Disease
Quick Facts About Pombiliti
Key Takeaways About Pombiliti
- Next-generation enzyme therapy: Pombiliti is designed with enhanced cellular uptake compared to earlier enzyme replacement therapies for Pompe disease, delivering more enzyme to affected muscle cells
- Always used with miglustat: Pombiliti must be co-administered with miglustat 65 mg capsules, which stabilises the enzyme in the bloodstream – do not use miglustat 100 mg capsules
- Biweekly hospital infusion: Administered as an intravenous infusion every two weeks, lasting approximately 4 hours, with home infusion possible after medical evaluation
- Common side effect – headache: Headache is the most frequently reported adverse effect; infusion-related reactions including allergic responses may also occur
- Adults only: Currently approved only for patients aged 18 years and older with late-onset Pompe disease
What Is Pombiliti and What Is It Used For?
Pombiliti (cipaglucosidase alfa) is an enzyme replacement therapy used to treat late-onset Pompe disease in adults. It is always used together with miglustat 65 mg capsules and works by replacing the deficient acid alpha-glucosidase (GAA) enzyme, breaking down glycogen that accumulates in muscles and causes progressive weakness.
Pombiliti belongs to a class of biological medicines known as enzyme replacement therapies (ERTs). It contains cipaglucosidase alfa, a recombinant (laboratory-produced) form of the human acid alpha-glucosidase enzyme. This enzyme is naturally present in the body and is essential for breaking down glycogen (a complex sugar stored in cells) within specialised cellular compartments called lysosomes. In Pompe disease, the body either produces insufficient amounts of this enzyme or produces an enzyme that does not function correctly.
Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare inherited metabolic disorder caused by mutations in the GAA gene. When the GAA enzyme is deficient, glycogen accumulates progressively in muscle cells throughout the body. This glycogen buildup damages the muscles over time, leading to a range of symptoms including progressive limb-girdle muscle weakness, respiratory insufficiency, and reduced exercise tolerance. Late-onset Pompe disease (LOPD) refers to cases that present after the first year of life, typically in childhood, adolescence, or adulthood, and follows a slower but steadily progressive course.
The affected muscles in LOPD include the skeletal muscles that control walking, climbing stairs, and lifting objects, as well as the respiratory muscles (particularly the diaphragm) that assist with breathing. Over time, untreated LOPD can lead to the need for mobility aids such as wheelchairs and respiratory support including ventilators. Some patients may also experience cardiac involvement, though this is more common in the infantile form of the disease.
What distinguishes Pombiliti from earlier enzyme replacement therapies is its enhanced glycan profile. Cipaglucosidase alfa is engineered with higher levels of bis-phosphorylated mannose-6-phosphate (bis-M6P) residues on its surface. These bis-M6P residues serve as targeting signals that bind to the cation-independent mannose-6-phosphate receptor (CI-MPR) on cell surfaces, facilitating more efficient uptake of the enzyme into the lysosomes of affected muscle cells where it is needed most.
Pombiliti is always administered together with miglustat 65 mg hard capsules, a small-molecule enzyme stabiliser. Miglustat binds to the active site of cipaglucosidase alfa in the bloodstream, protecting the enzyme from premature degradation and inactivation before it reaches its target tissues. This combination approach results in higher enzyme levels reaching the lysosomes compared to the enzyme alone. It is critically important that patients use only miglustat 65 mg capsules specifically approved for this combination – miglustat 100 mg capsules (a different medicinal product used to treat Gaucher disease) must not be used as a substitute.
Pompe disease is classified as a rare disease, affecting approximately 1 in 40,000 people worldwide. Pombiliti was approved by the European Medicines Agency (EMA) in 2023 and by the US Food and Drug Administration (FDA) in 2023 for the treatment of late-onset Pompe disease in adults. It is manufactured by Amicus Therapeutics and represents a significant advance in the treatment landscape for this condition.
What Should You Know Before Receiving Pombiliti?
Before starting Pombiliti, inform your doctor about all your medical conditions, particularly any history of severe allergic reactions to enzyme replacement therapies, heart disease, or lung disease. Pombiliti is contraindicated if you have ever had a life-threatening hypersensitivity reaction to cipaglucosidase alfa or miglustat.
Contraindications
You must not receive Pombiliti if any of the following apply to you:
- Life-threatening hypersensitivity to cipaglucosidase alfa, miglustat, or any of the other ingredients – if you have previously experienced a severe allergic reaction (anaphylaxis) to these substances that required emergency treatment
- Previous infusion that had to be stopped and could not be restarted due to life-threatening hypersensitivity reactions – this indicates a high risk of recurrence
If you are uncertain whether any of these conditions apply to you, speak to your doctor, pharmacist, or nurse before receiving Pombiliti.
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before using Pombiliti if you have experienced any of the following:
- Allergic reactions, including anaphylaxis: Severe, life-threatening allergic reactions can occur during or after the infusion. Symptoms may include difficulty breathing, swelling of the face, lips, tongue, or throat, hives, rash, chest tightness, dizziness, or rapid heartbeat. Your doctor may administer pre-medications (antihistamines, corticosteroids, and/or antipyretics) before each infusion to reduce this risk
- Infusion-related reactions (IRRs): These are common with enzyme replacement therapies and can occur during the infusion or in the hours following it. Symptoms may include flushing, chills, fever, headache, nausea, and vomiting. Most IRRs are mild to moderate, but severe reactions can occur. If a reaction develops, the infusion rate may be slowed or temporarily stopped
- Heart or lung disease: Pre-existing cardiac conditions (such as heart failure, arrhythmias, or coronary artery disease) and pulmonary conditions may worsen during or immediately after the infusion. Your doctor and nursing team will monitor your vital signs closely throughout the infusion. Inform them immediately if you experience shortness of breath, coughing, rapid or irregular heartbeat, or any other new symptoms
- Swelling in legs, widespread body swelling, severe skin rashes, or foamy urine: These symptoms may indicate a serious adverse reaction that requires the infusion to be stopped. Your doctor will evaluate whether you can continue receiving Pombiliti
Pre-treatment Medications
Your doctor may prescribe additional medications to be taken before the Pombiliti infusion to reduce the risk of infusion-related reactions. These pre-medications typically include:
- Antihistamines (such as diphenhydramine or cetirizine) to prevent or reduce allergic symptoms
- Corticosteroids (such as methylprednisolone or dexamethasone) to suppress immune-mediated reactions
- Antipyretics (such as paracetamol/acetaminophen) to prevent fever
The specific pre-medications and their doses will be determined by your treating physician based on your individual history and any previous reactions to infusions.
Children and Adolescents
Pombiliti should not be given to patients under 18 years of age. The safety and efficacy of Pombiliti in combination with miglustat have not been established in this age group. Children and adolescents with Pompe disease should be managed by specialist centres and may receive alternative enzyme replacement therapies that have been studied in paediatric populations.
Pregnancy and Breastfeeding
There is no clinical experience with the use of Pombiliti in combination with miglustat during pregnancy. You should not receive Pombiliti and/or take miglustat 65 mg capsules if you are pregnant. If you become pregnant, think you might be pregnant, or are planning to become pregnant, tell your doctor immediately. There may be risks to the unborn baby.
Pombiliti in combination with miglustat should not be used during breastfeeding. A decision must be made whether to discontinue breastfeeding or to discontinue the treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Contraception and fertility: Women of childbearing potential must use reliable contraception during treatment and for 4 weeks after stopping both medicines. Discuss appropriate contraceptive methods with your doctor.
Driving and Operating Machinery
You may feel dizzy, drowsy, or experience low blood pressure after receiving Pombiliti or after pre-treatment with other medications. If this happens, you should not drive or operate machinery until these symptoms have resolved. Wait until you feel fully recovered before driving or using tools or machines.
Sodium Content
Each vial of Pombiliti contains 10.5 mg of sodium (a component of table salt). This is equivalent to 0.52% of the recommended maximum daily dietary intake of sodium for an adult. Your doctor will take this into account if you are on a controlled sodium diet.
How Does Pombiliti Interact with Other Drugs?
Pombiliti must always be used with miglustat 65 mg capsules. Tell your doctor about all medications you are taking, including over-the-counter medicines and herbal supplements. Specific interaction studies with other drugs are limited, but certain alpha-glucosidase inhibitors should be avoided.
Because Pombiliti is a biological enzyme rather than a small-molecule chemical drug, it is not metabolised by the liver cytochrome P450 (CYP) enzyme system in the same way as most conventional medicines. This means that traditional drug-drug interactions mediated by CYP enzymes are not expected to be clinically significant. However, some pharmacological interactions are important to consider.
The most critical interaction is with miglustat. Pombiliti is specifically designed to be co-administered with miglustat 65 mg hard capsules. Miglustat acts as a pharmacological chaperone that stabilises cipaglucosidase alfa in the bloodstream, enhancing its delivery to target tissues. It is essential that patients use only the 65 mg miglustat capsules approved for use with Pombiliti. The 100 mg miglustat capsules (Zavesca), which are used to treat Gaucher disease type 1, must not be substituted.
Known Drug Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Miglustat 65 mg | Enzyme stabiliser (chaperone) | Required co-administration – stabilises cipaglucosidase alfa in the bloodstream | Always use together; take miglustat 1 hour before infusion (max 3 hours before) |
| Miglustat 100 mg (Zavesca) | Glucosylceramide synthase inhibitor | Different product; not interchangeable with miglustat 65 mg capsules | Do NOT use as substitute for miglustat 65 mg capsules |
| Miglitol | Alpha-glucosidase inhibitor (diabetes) | May theoretically interfere with the enzymatic activity of cipaglucosidase alfa | Discuss with your doctor; may need timing adjustments |
| Acarbose | Alpha-glucosidase inhibitor (diabetes) | May theoretically interfere with the enzymatic activity of cipaglucosidase alfa | Discuss with your doctor; may need timing adjustments |
| Other ERT (e.g. alglucosidase alfa) | Enzyme replacement therapy | Switching from another ERT requires coordinated transition | Your doctor will advise when to stop previous ERT before starting Pombiliti |
Always tell your doctor, pharmacist, or nurse about all medicines you are currently using, have recently used, or might use. This includes over-the-counter medicines, vitamins, and herbal products. Although Pombiliti itself has limited CYP-mediated interactions, the co-administered miglustat may interact with other medications, so a complete medication review is important.
What Is the Correct Dosage of Pombiliti?
The recommended dose of Pombiliti is 20 mg per kilogram of body weight, given as an intravenous infusion once every two weeks. It must be taken together with miglustat 65 mg capsules, which are swallowed 1 hour before the infusion starts.
Pombiliti is always administered by a doctor or nurse as an intravenous infusion (drip into a vein). It is not available in any self-administration form. The dosage is calculated individually based on your body weight.
Adults
Late-Onset Pompe Disease
Dose: 20 mg per kg body weight
Frequency: Once every 2 weeks (biweekly)
Route: Intravenous infusion
Infusion duration: Approximately 4 hours
The infusion rate is gradually increased during administration. The initial rate is typically 1 mg/kg/hour, increased by 2 mg/kg/hour every 30 minutes (if no signs of infusion-related reactions occur), up to a maximum rate of 7 mg/kg/hour.
Miglustat 65 mg Capsules (Co-administered)
Dose: As directed by your doctor (refer to miglustat 65 mg capsule package leaflet)
Timing: Take miglustat capsules exactly 1 hour before the Pombiliti infusion starts
Maximum delay: If there is a delay, the Pombiliti infusion must start no later than 3 hours after taking miglustat
Miglustat is taken on the same day as the Pombiliti infusion only. Do not take miglustat on non-infusion days unless specifically instructed by your doctor.
Children and Adolescents
Pombiliti is not approved for use in patients under 18 years of age. The safety and effectiveness of cipaglucosidase alfa in combination with miglustat have not been established in paediatric populations. Children and adolescents with Pompe disease should be referred to specialist metabolic centres for appropriate treatment options.
Switching from Another Enzyme Replacement Therapy
If you are currently receiving a different enzyme replacement therapy for Pompe disease (such as alglucosidase alfa), your doctor will coordinate the transition to Pombiliti. You will be told when to stop the previous treatment before starting Pombiliti. It is important to inform your doctor about when you received your last dose of the previous ERT.
Home Infusion
After your doctor has evaluated your treatment history and determined that it is safe, you may be eligible to receive Pombiliti infusions at home. Home infusions are administered by a qualified healthcare professional. If you experience any side effects during a home infusion, the healthcare professional can stop the infusion and provide appropriate medical treatment. Discuss the possibility of home infusion with your treating physician.
Missed Dose
If you miss a scheduled infusion, contact your doctor or nurse as soon as possible to arrange a new appointment. Pombiliti should be administered in combination with miglustat at least 24 hours after the last dose of miglustat was taken. It is important to maintain a regular infusion schedule to achieve optimal treatment outcomes.
Overdose
If you receive Pombiliti too quickly or at too high a dose, you may experience symptoms due to fluid overload, including shortness of breath, rapid heartbeat, or widespread swelling of the body. Tell your doctor or nurse immediately if you have difficulty breathing, feel swollen or bloated, or notice your heart racing during or after the infusion. The infusion rate will be slowed or stopped, and appropriate treatment will be given.
Stopping Pombiliti
Do not stop Pombiliti treatment without talking to your doctor. Pompe disease is a chronic, progressive condition, and discontinuing enzyme replacement therapy may lead to worsening of your symptoms, including increased muscle weakness and respiratory decline. If you are considering stopping treatment for any reason, discuss this thoroughly with your specialist physician so that the potential consequences can be evaluated and a management plan can be put in place.
What Are the Side Effects of Pombiliti?
The most common side effect of Pombiliti is headache, affecting more than 1 in 10 people. Common side effects include infusion-related reactions such as flushing, chills, fever, nausea, dizziness, fatigue, and muscle pain. Serious allergic reactions including anaphylaxis can occur but are uncommon.
Like all medicines, Pombiliti can cause side effects, although not everybody gets them. Pombiliti is always used together with miglustat, and side effects may occur with either medicine. Side effects are most commonly observed during the infusion (infusion-related reactions) or shortly afterwards. You must tell your doctor or nurse immediately if you experience any infusion-related reaction or allergic reaction. Some of these reactions can become serious and life-threatening.
- Severe allergic reactions (anaphylaxis): difficulty breathing, swelling of face, lips, tongue or throat, widespread hives, chest tightness, rapid drop in blood pressure, loss of consciousness
- Severe breathing difficulties, persistent cough, or wheezing
- Rapid or irregular heartbeat, chest pain
- Severe widespread swelling of the body or face
- Foamy urine, leg swelling, or severe skin rashes
Very Common
May affect more than 1 in 10 people
- Headache
Common
May affect up to 1 in 10 people
- Serious, life-threatening allergic reactions (anaphylaxis)
- Dizziness
- Tremor (shaking)
- Drowsiness
- Taste disturbances
- Paraesthesia (numbness, tingling, pins and needles)
- Rapid heart rate (tachycardia)
- Flushing
- Low blood pressure (hypotension)
- Shortness of breath (dyspnoea)
- Cough
- Diarrhoea
- Nausea
- Abdominal pain
- Flatulence (gas)
- Bloating
- Vomiting
- Hives (urticaria)
- Itching (pruritus)
- Rash
- Excessive sweating
- Painful muscle cramps
- Muscle pain (myalgia)
- Muscle weakness
- Joint pain (arthralgia)
- Fatigue
- Fever (pyrexia)
- Chills
- Chest discomfort
- Swelling at the infusion site
- Pain
- Swelling of hands, feet, ankles, or legs (peripheral oedema)
- High blood pressure (hypertension)
Uncommon
May affect up to 1 in 100 people
- Allergic reactions
- Balance problems
- Burning sensation
- Migraine
- Feeling faint (presyncope)
- Unusual paleness of the skin
- Asthma
- Wheezing
- Mouth and throat discomfort
- Throat swelling
- Indigestion (dyspepsia)
- Oesophageal pain or spasm
- Mouth pain or discomfort
- Swollen tongue
- Skin discolouration
- Skin swelling
- Flank pain (between hip and ribs)
- Muscle fatigue
- Muscle stiffness
- Weakness (asthenia)
- Facial pain (cheeks, gums, lips, chin)
- Infusion site pain
- General malaise
- Chest pain
- Facial swelling
- Changes in body temperature
- Skin excoriations (scratches or abrasions)
Reporting Side Effects
If you experience any side effects, including any not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national pharmacovigilance authority (for example, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the FDA MedWatch programme in the US, or the relevant national agency in your country). By reporting side effects, you can help provide more information on the safety of this medicine.
How Should Pombiliti Be Stored?
Pombiliti is stored and handled by your healthcare team. Unopened vials are kept refrigerated at 2–8°C and protected from light. Once prepared, the infusion solution should be used immediately or can be stored for up to 6 hours at room temperature.
As Pombiliti is administered in a hospital or clinic setting, you will not need to store this medicine yourself. However, the following storage information applies to your healthcare team:
- Unopened vials: Store in a refrigerator at 2°C–8°C (36°F–46°F). Keep the vial in the outer carton to protect from light
- After reconstitution: The reconstituted solution should be diluted and used immediately. If necessary, the diluted infusion bag may be stored for up to 6 hours at 20°C–25°C (68°F–77°F) or up to 24 hours at 2°C–8°C (36°F–46°F)
- Do not use after the expiry date stated on the vial and carton after "EXP". The expiry date refers to the last day of that month
- Keep out of the sight and reach of children
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.
What Does Pombiliti Contain?
Each vial of Pombiliti contains 105 mg of cipaglucosidase alfa as the active substance. After reconstitution with water for injection, the solution contains 15 mg/ml of cipaglucosidase alfa. The final diluted concentration for infusion is between 0.5 mg/ml and 4 mg/ml.
Active Ingredient
The active substance is cipaglucosidase alfa. Each vial contains 105 mg of cipaglucosidase alfa. After reconstitution with 7.2 ml of water for injections, the solution in the vial contains 15 mg of cipaglucosidase alfa per ml. The recommended final concentration of cipaglucosidase alfa diluted in the intravenous bag is between 0.5 mg/ml and 4 mg/ml.
Other Ingredients (Excipients)
- Sodium citrate dihydrate (E331)
- Citric acid monohydrate (E330)
- Mannitol (E421)
- Polysorbate 80 (E433)
Appearance and Pack Sizes
Pombiliti is a white to slightly yellowish powder. After reconstitution, it is a clear to opalescent, colourless to slightly yellow solution, free of foreign particles and practically free of white to translucent particles. The reconstituted solution must be further diluted in an intravenous infusion bag with sodium chloride 9 mg/ml (0.9%) solution for injection before administration.
Pombiliti is supplied as a powder for concentrate for solution for infusion in a single-use vial. It is available in pack sizes of 1 vial, 10 vials, or 25 vials. Not all pack sizes may be marketed in your country.
Pombiliti is manufactured by Manufacturing Packaging Farmaca (MPF) B.V. (Netherlands) and marketed by Amicus Therapeutics Europe Limited (Dublin, Ireland). For further information, contact your local Amicus Therapeutics representative or visit the European Medicines Agency (EMA) website for the full product information.
Frequently Asked Questions About Pombiliti
Pombiliti (cipaglucosidase alfa) is used in combination with miglustat 65 mg capsules as enzyme replacement therapy for the treatment of late-onset Pompe disease in adults. Pompe disease is a rare inherited metabolic disorder caused by deficiency of the acid alpha-glucosidase (GAA) enzyme, leading to glycogen accumulation in muscles and progressive muscle weakness. Pombiliti replaces the missing enzyme and helps break down the excess glycogen.
Pombiliti is given as an intravenous infusion (drip into a vein) by a healthcare professional. The infusion takes approximately 4 hours and is administered once every two weeks. Before each infusion, you must take miglustat 65 mg capsules exactly 1 hour before the infusion starts (and no more than 3 hours before). The infusion rate is gradually increased during the session provided no infusion-related reactions occur.
The most common side effect is headache, affecting more than 1 in 10 people. Common side effects (up to 1 in 10 people) include dizziness, tremor, drowsiness, rapid heart rate, flushing, low blood pressure, shortness of breath, cough, nausea, diarrhoea, abdominal pain, vomiting, itching, rash, muscle pain, joint pain, fatigue, fever, chills, and swelling at the infusion site. Serious allergic reactions (anaphylaxis) can occur but are less frequent. Report any unusual symptoms to your doctor immediately.
Yes, home infusion of Pombiliti may be possible after your doctor has carefully evaluated whether it is safe for you. This decision is based on your history of infusion-related reactions, overall health, and practical considerations. If approved for home infusion, a qualified healthcare professional will administer the treatment in your home and can stop the infusion and provide medical treatment if any side effects occur.
Miglustat 65 mg capsules act as an enzyme stabiliser (pharmacological chaperone). When taken before the Pombiliti infusion, miglustat binds to cipaglucosidase alfa in the bloodstream and protects it from premature degradation. This means more active enzyme reaches the affected muscle cells. It is critical to use only the 65 mg miglustat capsules specifically designed for this purpose – the 100 mg miglustat capsules (Zavesca, used for Gaucher disease) must not be used as a substitute.
There is no clinical experience with Pombiliti in combination with miglustat during pregnancy. You should not receive Pombiliti if you are pregnant. Women of childbearing potential must use reliable contraception during treatment and for 4 weeks after stopping both medicines. If you become pregnant or plan to become pregnant, tell your doctor immediately so that alternative management options can be discussed.
References
- European Medicines Agency (EMA). Pombiliti (cipaglucosidase alfa) – Summary of Product Characteristics. 2023. Available at: EMA EPAR Pombiliti.
- US Food and Drug Administration (FDA). Pombiliti Prescribing Information. 2023.
- Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Molecular Genetics and Metabolism. 2010;99(1):26–33.
- Schoser B, Roberts M, Gruszczynski J, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. The Lancet Neurology. 2024;23(2):148–159.
- American College of Medical Genetics and Genomics (ACMG). Pompe Disease Diagnosis and Management Guidelines. 2023.
- World Health Organization (WHO). International Classification of Diseases (ICD-10) – E74.0 Glycogen storage disease. 2023.
- van der Ploeg AT, Reuser AJJ. Pompe's disease. The Lancet. 2008;372(9646):1342–1353.
- Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Annals of Translational Medicine. 2019;7(13):284.
About the Medical Editorial Team
All content on iMedic is reviewed by our independent Medical Review Board, consisting of board-certified specialists in metabolic medicine, neurology, and clinical pharmacology. Our team follows international guidelines (EMA, FDA, ACMG) and the GRADE evidence framework to ensure the highest standards of medical accuracy.
This article was written and reviewed according to iMedic's editorial standards. We rely exclusively on peer-reviewed sources, international clinical guidelines, and official regulatory documents. iMedic receives no pharmaceutical company funding and maintains complete editorial independence.
For questions about this article or our editorial process, please contact our editorial team.